Neuland Laboratories Limited

NEULANDLAB

INE794A01010

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:47 2024-04-18 am EDT			5-day change	1st Jan Change
7,655 ^INR	+1.79%		+23.87%	+44.77%

Apr. 12	INDIA STOCKS-Financials drag Indian shares, hit by fading US rate cut hopes	RE
Mar. 31	Neuland Laboratories Limited Announces Resignation of P.V. Maiya as Director	CI

Neuland Laboratories Limited(BSE:524558) added to S&P Global BMI Index

September 20, 2021 at 12:00 am EDT

Latest news about Neuland Laboratories Limited

INDIA STOCKS-Financials drag Indian shares, hit by fading US rate cut hopes	Apr. 12	RE
Neuland Laboratories Limited Announces Resignation of P.V. Maiya as Director	Mar. 31	CI
Neuland Laboratories Names Chief Quality Officer	Mar. 06	MT
Neuland Laboratories Limited Announces Appointment of Ashutosh Kumar Sinha as Chief Quality Officer	Mar. 06	CI
Transcript : Neuland Laboratories Limited, Q3 2024 Earnings Call, Feb 09, 2024	Feb. 09
Neuland Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Neuland Laboratories Names Chief Scientific Officer	Nov. 22	MT
Neuland Laboratories Limited Announces the Appointment of Dr. Sharadsrikar V.Kotturi as Chief Scientific Officer	Nov. 22	CI
Transcript : Neuland Laboratories Limited, Q2 2024 Earnings Call, Nov 07, 2023	Nov. 07
Neuland Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 07	CI
Neuland Laboratories Limited Announces Resignation of Humayun Dhanrajgir as Independent Director	23-09-25	CI
Transcript : Neuland Laboratories Limited, Q1 2024 Earnings Call, Aug 03, 2023	23-08-03
Neuland Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-03	CI
Neuland Laboratories Limited Approves Final Dividend for the Financial Year 2022-23	23-07-27	CI
Neuland Laboratories Limited Announces Director Appointments	23-07-27	CI
Transcript : Neuland Laboratories Limited, Q4 2023 Earnings Call, May 11, 2023	23-05-11
Neuland Laboratories' Consolidated Net Profit Soars in Fiscal Q4	23-05-11	MT
Neuland Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-11	CI
Neuland Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-11	CI
Neuland Laboratories Limited Recommends Final Dividend for the Financial Year 2022-23	23-05-11	CI
Crisil Raises Neuland Laboratories Rating to A; Outlook Stable	23-04-25	MT
Transcript : Neuland Laboratories Limited, Q3 2023 Earnings Call, Feb 14, 2023	23-02-14
Neuland Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Neuland Laboratories to Sell Company Land in Hyderabad, India for $14 Million	22-11-23	MT
Neuland Laboratories Appoints CFO	22-11-23	MT

Chart Neuland Laboratories Limited

Duration

Period

More charts

Neuland Laboratories Limited is an India-based company, which is engaged in manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industryâs chemistry needs. The Company provide solutions across the full range of the pharmaceutical industryâs chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.

Sector

Pharmaceuticals

Calendar

2024-05-06 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Neuland Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7,655 INR

Average target price

8,300 INR

Spread / Average Target

+8.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NEULAND LABORATORIES LIMITED	+44.77%	1.15B
ELI LILLY AND COMPANY	+27.97%	676B
NOVO NORDISK A/S	+23.58%	554B
JOHNSON & JOHNSON	-7.02%	349B
MERCK & CO., INC.	+14.85%	318B
ABBVIE INC.	+6.25%	291B
ASTRAZENECA PLC	+2.96%	210B
NOVARTIS AG	-0.41%	204B
ROCHE HOLDING AG	-10.02%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals